|
SAN FRANCISCO (AP) - Genentech Inc., one of the world's largest biotechnology companies, continued its hot earnings streak, beating Wall Street expectations with a 41 percent boost in second-quarter profit on sales of its best-selling cancer drug.
The company reported Wednesday that it earned $747 million, or 70 cents per share, compared with profit of $531 million, or 49 cents per share, during the year-ago period.
Revenue rose 36 percent to $3 billion from $2.2 billion.
|
|